Kathleen Moore to Cisplatin
This is a "connection" page, showing publications Kathleen Moore has written about Cisplatin.
Connection Strength
0.889
-
Treatment Advances in Locoregionally Advanced and Stage IVB/Recurrent Cervical Cancer: Can We Agree That More Is Not Always Better? J Clin Oncol. 2015 Jul 01; 33(19):2125-8.
Score: 0.447
-
A phase I study of intravenous or intraperitoneal platinum based chemotherapy in combination with veliparib and bevacizumab in newly diagnosed ovarian, primary peritoneal and fallopian tube cancer. Gynecol Oncol. 2020 01; 156(1):13-22.
Score: 0.153
-
A phase I trial of tailored radiation therapy with concomitant cetuximab and cisplatin in the treatment of patients with cervical cancer: A gynecologic oncology group study. Gynecol Oncol. 2012 Dec; 127(3):456-61.
Score: 0.093
-
A comparison of cisplatin/paclitaxel and carboplatin/paclitaxel in stage IVB, recurrent or persistent cervical cancer. Gynecol Oncol. 2007 May; 105(2):299-303.
Score: 0.063
-
Incorporation of whole pelvic radiation into treatment of stage IVB cervical cancer: A novel treatment strategy. Gynecol Oncol. 2020 01; 156(1):100-106.
Score: 0.038
-
A Phase I Evaluation of Extended Field Radiation Therapy With Concomitant Cisplatin Chemotherapy Followed by Paclitaxel and Carboplatin Chemotherapy in Women With Cervical Carcinoma Metastatic to the Para-aortic Lymph Nodes: An NRG Oncology/Gynecologic Oncology Group Study. Gynecol Oncol. 2018 11; 151(2):202-207.
Score: 0.035
-
MICU1 drives glycolysis and chemoresistance in ovarian cancer. Nat Commun. 2017 05 22; 8:14634.
Score: 0.032
-
A phase I study of IV doxorubicin plus intraperitoneal (IP) paclitaxel and IV or IP cisplatin in endometrial cancer patients at high risk for peritoneal failure (GOG 9920): an NRG Oncology/Gynecologic Oncology Group study. Gynecol Oncol. 2015 Jul; 138(1):36-40.
Score: 0.028